Ginkgo bioworks partners with universal cells, an astellas company, to advance next-generation ipsc-derived cell therapies for solid tumors

Collaboration leverages ginkgo's cell engineering and screening platform to enhance the potency and persistence of universal cells' ipsc-derived immune cell therapeutics boston , jan. 13, 2025 /prnewswire/ -- ginkgo bioworks (nyse: dna), which is building the leading platform for cell programming and biosecurity, today announced a research collaboration with universal cells, an astellas company, to optimize next-generation induced pluripotent stem cell (ipsc)-derived cancer cell therapies. this collaboration underscores ginkgo's capacity to deploy high-throughput biological approaches to tackle the complex challenge set associated with development of therapies targeting solid tumors.
DNA Ratings Summary
DNA Quant Ranking